Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Expert Opin Pharmacother. 2016 Nov 7;17(18):2375–2389. doi: 10.1080/14656566.2016.1252333

Figure 1. Optimizing myelofibrosis therapy. Potential combination partners of ruxolitinib that have been or are being studied in clinical trials.

Figure 1

Abbreviations: Imids, immunomodulatory agents, e.g., thalidomide, lenalidomide, pomalidomide. ActRIIA ligand traps, activin receptor type IIA ligand traps, e.g., sotatercept, luspatercept; HMAs, hypomethylating agents, e.g., azacitidine, decitabine; HDAC inhibitors, histone deacetylase inhibitors, e.g., panobinostat, pracinostat; PI3 kinase inhibitors, phophsatidylinositol-3-kinase inhibitors, e.g., buparlisib, INCB050465.